ArticleFrontiers in surgery2025
Optimal treatment strategy and prognostic analysis for patients with locally advanced Upper Tract Urothelial Carcinoma.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to identify the optimal treatment strategy and conduct a prognostic analysis for patients with locally advanced Upper Tract Urothelial Carcinoma (UTUC). Methods and materials: The study included 3,829 patients diagnosed with pT3-4N0/+M0 UTUC from 2004 to 2015, with data obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were randomly assigned to a training group (70%) and a validation group (30%) for nomogram development. Variables that were significant in univariate COX regression analysis ( Results: Within the pN+ subgroup, the combination of surgery with both adjuvant chemotherapy and radiotherapy (S + R + C) group and S + C group yielded superior results over the S group, with the S + R + C group regimen showing the most favorable outcomes. The 3-year OS rates for patients in the S + R + C, S + C, and S groups were recorded as 40.00%, 31.43%, and 12.5%. The corresponding 3-year CSS rates were 47.56%, 34.02%, and 17.5%. Multivariate COX regression analysis identified age, primary tumor location, T and N stages, treatment modality, tumor size, and lymph node count as significant predictors of OS and CSS. These factors were integrated into precisely developed nomograms for predicting OS and CSS, with concordance indices of 0.651 and 0.667 in both sets. Conclusion: For patients with pT3-4N + M0 stage UTUC, the addition of radiotherapy to the surgical and chemotherapy regimen has proven to enhance survival rates. Our predictive nomogram reliably forecasts OS and CSS rates for locally advanced patients. This tool can assist clinicians in identifying high-risk individuals, thereby aiding in the formulation of informed treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.